In vitro modulation of naturally occurring flavonoids on cytochrome P450 2A6 (CYP2A6) activity

Xenobiotica

Volumn 40, Issue 7, 2010, Pages 458-466

  Tiong, K H ^a   Yiap, B C ^a   Tan, E L ^a   Ismail, R ^b   Ong, C E ^c  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^b INSTITUTE FOR RESEARCH IN MOLECULAR MEDICINE INFORMM   (Malaysia)

^c MONASH UNIVERSITY MALAYSIA   (Malaysia)

Author keywords

CDNA expressed CYP2A6; Coumarin 7 hydroxylation; Flavonoids; Inhibition

Indexed keywords

ACACETIN; COMPLEMENTARY DNA; COUMARIN 7 HYDROXYLASE; CYTOCHROME P450 2A6; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; FISETIN; FLAVANONE DERIVATIVE; FLAVONE DERIVATIVE; FLAVONOID; FLAVONOL DERIVATIVE; GALANGIN; HYDROXYL GROUP; KAEMPFEROL; MORIN; MYRICETIN; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; QUERCETIN; RUTOSIDE; COUMARIN 7; COUMARIN DERIVATIVE; CYP2A6 PROTEIN, HUMAN; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; GLYCOSYLATION; HYDROXYLATION; IN VITRO STUDY; STRUCTURE ACTIVITY RELATION; DRUG EFFECTS; FLUOROMETRY; GENE EXPRESSION REGULATION; HUMAN; KINETICS; LIVER; METABOLISM;

ARYL HYDROCARBON HYDROXYLASES; COUMARINS; CYTOCHROME P-450 CYP2A6; ENZYME INHIBITORS; FLAVONOIDS; FLUOROMETRY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYDROXYLATION; IMIDAZOLES; IN VITRO TECHNIQUES; KINETICS; LIVER; NADP; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77953591766     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498251003786749     Document Type: Article

References (39)

1. Aklilu M, Kindler HL, Donehower RC, Mani S, Vokes EE. (2003). Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol 14:1270-1273.
2. Bradford MM. (1976). A dye binding assay for protein. Anal Biochem 72:248-254.
3. Breinholt VM, Offord EA, Brouwer C, Nielsen SE, Brøsen K, Friedberg T. (2002). In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. Food Chem Toxicol 40:609-616.
4. Chae YH, Marcus CB, Ho DK, Cassady JM, Baird WM. (1991). Effects of synthetic and naturally occurring flavonoids on benzo(a) pyrene metabolism by hepatic microsomes prepared from rats treated with cytochrome P-450 inducers. Cancer Lett 60:15-24.
5. Chan WK, Nguyen LT, Miller VP, Harris RZ. (1998). Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci 62:PL135-PL142.
6. Donato MT, Jiménez N, Castell JV, Gómez-Lechón MJ. (2004). Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. Drug Metab Dispos 32:699-706.
7. Doostdar H, Burke MD, Mayer RT. (2000). Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 144:31-38.
8. Fink BN, Steck SE, Wolff MS, Britton JA, Kabat GC, Schroeder JC, Teitelbaum SL, Neuqut AI, Gammon MD. (2007). Dietary flavonoid intake and breast cancer risk among women on Long Island. Am J Epidemiol 165:514-523.
9. Galati G, O'Brien PJ. (2004). Serial review: flavonoids and isoflavones (phytoestrogens): absorption, metabolism and bioactivity. Free Radic Biol Med 37:287-303.
10. Ghosal A, Hapangama N, Yuan Y, Lu X, Horne D, Patrick JE, Zbaida S. (2003). Rapid determination of enzyme activities of recombinant human cytochrome P450, human liver microsomes and hepatocytes. Biopharm Drug Dispos 24:375-384.
11. Glusker JP, Rossi M. (1986). Molecular aspects of chemical carcinogens and bioflavonoids.In: Cody V, Middleton E, Harborne JB, eds. Plant flavonoids in biology and medicine: biochemical, pharmacological and structure-activity relationships. New York, NY: A.R. Liss. p. 395-410.
12. Harborne JB, Williams CA. (2000). Advances in flavonoid research since 1992. Phytochemistry 55:481-504.
13. Havsteen BH. (2002). The biochemistry and medical significance of the flavonoids. Pharmacol Ther 96:67-202.
14. Hodek P, Trefil P, Stiborová M. (2002). Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem Biol Interact 139:1-21.
15. Khlebnikov AI, Schepetkin IA, Domina NG, Kirpotina LN, Quinn MT. (2007). Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems. Bioorg Med Chem 15:1749-1770.
16. Knekt P, Järvinen R, Seppänen R, Hellövaara M, Teppo L, Pukkala E, Aromaa A. (1997). Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. Am J Epidemiol 146:223-230. (Pubitemid 27329723)
17. Le Marchand L, Murphy SP, Hankin JH, Wilkens LR, Kolonel LN. (2000). Intake of flavonoids and lung cancer. J Natl Cancer Inst 92:154-160.
18. Lee H, Yeom H, Kim YG, Yoon CN, Jin C, Choi JS, Kim BR, Kim DH. (1998). Structure-related inhibition of human hepatic caffeine N3-demethylation by naturally occurring flavonoids. Biochem Pharmacol 55:1369-1375.
19. Lewis DF, Lake BG. (2002). Species differences in coumarin metabolism: a molecular modelling evaluation of CYP2A interactions. Xenobiotica 32:547-561.
20. Li Y, Wang E, Patten CJ, Chen L, Yang CS. (1994). Effects of flavonoids on cytochrome P450-dependent acetaminophen metabolism in rats and human liver microsomes. Drug Metab Dispos 22:566-571.
21. Middleton E Jr, Kandaswami C, Theoharides TC. (2000). The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52:673-751.
22. Omura T, Sato R. (1964). The carbon monoxide-binding pigment of liver microsomes. J Biochem 239:2370-2378.
23. Pelkonen O, Rautio A, Raunio H, Pasanen M. (2000). CYP2A6: a human coumarin 7-hydroxylase. Toxicology 144:139-147.
24. Raunio H, Rautio A, Gullstén H, Pelkonen O. (2001). Polymorphisms of CYP2A6 and its practical consequences. Br J Clin Pharmacol 52:357-363.
25. Ren W, Qiao Z, Wang H, Zhu L, Zhang L. (2003). Flavonoids: promising anticancer agents. Med Res Rev 23:519-534.
26. Ritschel WA, Brady ME, Tan HS, Hoffmann KA, Yiu IM, Grummich KW. (1977). Pharmacokinetics of coumarin and its 7-hydroxy-metabolites upon intravenous and peroral administration of coumarin in man. Eur J Clin Pharmacol 12:457-461.
27. Robak J, Gryglewski RJ. (1996). Bioactivity of flavonoids. Pol J Pharmacol 48:555-564.
28. Schwab GE, Raucy JL, Johnson EF. (1988). Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone. Mol Pharmacol 33:493-499.
29. Sellers EM, Kaplan HL, Tyndale RF. (2000). Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin Pharmacol Ther 68:35-43.
30. Seyoum A, Asres K, El-Fiky FK. (2006). Structure-radical scavenging activity relationships of flavonoids. Phytochemistry 67:2058-2070.
31. Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, Zacarola PF, Muzikansky A, Wright JJ, Lynch TJ Jr, Rollins BJ. (2001). A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 7:1590-1599.
32. Singh R, Ting JG, Pan Y, Teh LK, Ismail R, Ong CE. (2008). Functional role of Ile264 in CYP2C8: mutations affect haem incorporation and catalytic activity. Drug Metab Pharmacokinet 23:165-174.
33. Strobel HW, Dignam JD. (1978). Purification and properties of NADPHcytochrome P-450 reductase. Meth Enzymol 52:89-96.
34. Strom SS, Yamamura Y, Duphorne CM, Spitz MR, Babaian RJ, Pillow PC, Hursting SD. (1999). Phytoestrogen intake and prostate cancer: a case-control study using a new database. Nutr Cancer 33:20-25.
35. Tsyrlov IB, Mikhailenko VM, Gelboin HV. (1994). Isozyme- and species-specific susceptibility of cDNA-expressed CYP1A P-450s to different flavonoids. Biochim Biophys Acta 1205:325-335.
36. van Veldhuizen PJ, Faulkner JR, Lara PN Jr, Gumerlock PH, Goodwin JW, Dakhil SR, Gross HM, Flanigan RC, Crawford ED. (2005). A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109. Cancer Chemother Pharmacol 56:39-45.
37. Xu C, Goodz S, Sellers EM, Tyndale RF. (2002). CYP2A6 genetic variation and potential consequences. Adv Drug Deliv Rev 54:1245-1256.
38. Yano JK, Hsu MH, Griffin KJ, Stout CD, Johnson EF. (2005). Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat Struct Mol Biol 12:822-823.
39. Zhai S, Dai R, Friedman FK, Vestal RE. (1998). Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids. Drug Metab Dispos 26:989-992. (Pubitemid 28478260)